NX PharmaGen Inc. is dedicated to advancing personalized medicine through innovative technologies that enhance patient care. The company focuses on next-generation molecular diagnostics and imaging products that aim to improve patient outcomes, assist physician decision-making, and optimize payer economics. One of their notable developments is Gleolan, a fluorescence-guided resection imaging agent specifically designed for brain tumor patients, which was successfully launched in the U.S. following FDA approval. This technology exemplifies NX PharmaGen's commitment to fostering advancements that can significantly impact clinical practices and patient management.

In addition to imaging technologies, NX PharmaGen is also pioneering exosome-based diagnostics through its subsidiaries, NX Prenatal Inc. and Nexosome Oncology. NX Prenatal has made significant strides in maternal-fetal-infant health by demonstrating the ability to detect biomarker panels from circulating maternal-fetal exosomes as early as 10-12 weeks of gestation, which can predict adverse pregnancy outcomes. Meanwhile, the Nexosome Oncology division is exploring the use of exosome-focused liquid biopsies in cancer diagnostics, providing insights into the molecular characteristics of tumors that can inform treatment strategies. Together, these technologies represent NX PharmaGen's innovative approach to addressing critical healthcare challenges.

United States

NX PharmaGen develops blood-based molecular diagnostic testing products.

4350 Brownsboro Road, Louisville, Kentucky, USA, 40207

NX PharmaGen Inc.

NX PharmaGen Inc.

Company Details